Camlin Fine Sciences Limited

Camlin Fine Sciences Limited

CAMLINFINE.BO
Camlin Fine Sciences LimitedIN flagBombay Stock Exchange
133.00
INR
+0.30
- -
25.56BMarket Cap
Camlin Fine Sciences Limited
CAMLINFINE.BO
(Bombay Stock Exchange)

Recent

price

133.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
-0.23
35.13
38.95
52.83
57.22
49.73
50.82
63.13
70.75
82.01
92.68
97.42
97.58
84.96
94.06
91.07
93.33
Revenue per Share
0.75
0.4
1.57
2.98
5.64
3.64
-1.07
-2.64
0.05
2.44
4.03
4.21
3.04
-5.49
-8.03
1.46
1.46
Basic EPS, GAAP
-0.92
-4.84
3.59
-0.99
1.85
0.46
-3.8
-3.08
-6.31
-3.88
2.65
-4.74
-5.45
4.64
-1.12
1.29
- -
Free Cash Flow per Basic Share
0.12
0.19
0.24
0.29
0.34
0.44
0.45
- -
0.5
0.23
0.43
0.05
0.81
1.66
- -
- -
- -
Dividend per Share
0.98
1.51
2.52
4.9
10
13.29
10.78
7.59
6.37
9.39
13.24
17.21
18.59
14.53
6.84
1.02
1.02
Book Value per Share
4.6
4.72
6.06
9.28
12.47
17.14
17.6
32.29
29.31
31.49
51.01
47.8
44.25
47.15
47.19
39.03
39.04
Tangible Book Value per Share
95
95
96
96
98
98
104
112
124
124
126
144
171
169
173
189
189
Basic Weighted Avg Shares
-22
3,352
3,736
5,087
5,583
4,893
5,284
7,101
8,781
10,179
11,712
14,044
16,713
14,362
16,287
17,233
17,654
Sales/Revenue/Turnover
-6.1
6.83
10.97
11.36
13.84
15.74
2.86
-0.89
5.11
10.06
13.58
7.55
9.69
11.4
9.52
2.09
8.42
Operating Margin (%)
56
136
136
118
162
171
218
267
290
328
443
560
625
786
737
740
733
Depreciation Expense
71
38
151
287
550
358
-112
-296
6
303
510
607
521
-928
-1,390
276
276
Net Income, GAAP
19.17
65.04
35.66
17.57
- -
28.39
- -
- -
81.99
48.75
37.81
35.76
50.47
9.61
0.13
- -
- -
Effective Tax Rate (%)
-327.91
1.13
4.04
5.64
9.86
7.32
-2.11
-4.17
0.07
2.98
4.35
4.32
3.12
-6.46
-8.54
1.6
1.56
Profit Margin (%)
439
105
199
109
372
194
337
1,946
2,121
1,271
3,171
2,983
2,948
2,684
3,372
2,621
2,621
Working Capital
682
330
377
285
281
214
513
1,102
1,936
2,212
2,817
4,047
4,224
3,499
2,934
3,370
3,370
LT Debt
465
529
654
933
1,349
1,811
2,302
4,334
4,303
4,601
7,132
7,651
8,241
8,570
8,748
10,008
10,008
Total Equity
0.11
5.54
14.77
23.32
- -
15.31
- -
- -
0.98
5.69
8.97
5.18
5.31
9.35
10.07
- -
- -
Return on Invested Capital (%)
22.33
9.02
10.89
27.59
- -
15.42
- -
- -
0.56
6.82
8.16
9.39
8.33
-1.91
-5.03
- -
- -
Return on Capital (%)
94.02
31.96
78.16
80.51
76.05
31.37
-9.2
-30.02
0.7
31.01
35.92
29.21
18.4
-32.9
-76.4
40.15
40.15
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
3,624
- -
3,831
LT Borrowings
2,901
- -
3,026
LT Finance Leases
193
- -
344
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
188
- -
192
Market Capitalization
35,531
27,646
18,338

Working Capital

FRC

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
11,670
- -
12,365
Cash, Cash Equivalents & STI
1,628
- -
2,111
Accounts Receivable, Net
3,258
- -
3,730
Inventories
5,310
- -
5,037
Total Current Liabilities
8,564
- -
9,744
Payables & Accruals
- -
- -
- -
ST Debt
3,624
- -
3,831
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
21.21%
7.1%
14.41%
Free Cash Flow
-187.56%
-160.4%
-225.97%
Net Income, GAAP
480.99%
-68.61%
-119.87%
Sales/Revenue/Turnover
14.11%
8.81%
5.81%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
4,196
4,059
3,859
3,837
14,362
2025
3,809
4,173
4,310
4,316
16,287
2026
4,236
4,598
4,572
4,248
17,233

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.94
-1.14
-0.67
- -
-5.49
2025
-1.99
-5.89
-0.24
-0.04
-8.03
2026
-0.53
-0.77
-1.91
4.59
1.46

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1.66
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Camlin Fine Sciences Limited Camlin Fine Sciences Limited manufactures specialty chemicals focused on shelf-life extension solutions, aroma ingredients, and performance chemicals for industries including food and beverages, animal nutrition, pet food, petrochemicals, pharmaceuticals, agrochemicals, and polymers. The company produces antioxidants such as tert-Butylhydroquinone (TBHQ) and Butylated hydroxyanisole (BHA), where it holds global leadership; natural alternatives under brands like Xtendra, NaSure, and Ezential for food protection in snacks, bakery, meat, poultry, and biodiesel; aroma compounds including vanillin and ethyl vanillin under adorr, Vanesse, and Evanil for flavors, fragrances, incense, and pharmaceuticals; performance chemicals such as hydroquinone, catechol, and derivatives under Dinamic for petrochemicals, dyes, pigments, and polymers; and innovative products like Biosus vegan DHA from algae and floral boosters for enhanced aroma in consumer goods. Founded in 1993 and headquartered in Mumbai, India, Camlin Fine Sciences Limited operates manufacturing facilities and offices across India, Italy, Belgium, France, Mexico, Brazil, the United States, Singapore, and other regions in Asia, Europe, the Americas, and the Middle East & Africa, serving a global sales network in over 160 locations with more than 1,000 employees and annual turnover exceeding USD 200 million. Recent strategic expansions include the 2024 acquisition of Vitafor Invest NV in Belgium by its Mexican subsidiary Dresen Quimica to bolster animal nutrition capabilities; an $11 million offshore funding in late 2024 to secure full ownership of Dresen Quimica from its joint venture partner; and the November 2025 completion of a majority 78.68% stake acquisition in French firm Vinpai S.A. via share swaps, convertible bonds worth €3.3 million, and tender offers, enhancing natural functional ingredients from algae, plants, and fibers to tap sustainable clean-label trends in specialty chemicals.